Investors.gilead.com
Gilead Sciences, Inc.
- This Approval Supports Veklury’s Strong Safety Profile and Makes Veklury the Only Approved COVID-19 Antiviral Treatment Across all Stages of Liver Disease - Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) approved a supplemental new drug application (sNDA) for the use of Veklury® (remdesivir) with no dose adjustments to treat COVID-19
Actived: 7 days ago
Gilead Sciences, Inc.
WEBIR Contact. Gilead Investor Relations. (650) 574-3000. [email protected].
Gilead Sciences, Inc.
WEBIR Contact. Gilead Investor Relations. (650) 574-3000. [email protected].
Top Categories
Popular Searched
› Bronson health rehab careers
› Cuban mental health articles
› George bush health condition
› Healthcare expenditure over time
› Doctors who take molina health care
› United health care good insurance
Recently Searched
› Samuel dixon family health center
› Brainscape healthy lifestyle test
› What is behavioral health experience
› Rochester regional health behavioral health
› Birmingham city university health school
› Factors indicating economic health
› Durable power of healthcare attorney
› Coal inhalation and human health
› Best value healthcare lakeland fl